Flavia Mendes, MD
Hepatology · Miami, FLNPI 1487628582
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,620 of the $6,087 with a category attached, or 75.9%. Intercept Pharmaceuticals, Inc. accounts for 76.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2020 at $3,837 and has fallen 94.4% since, to $216 in 2025.
Across 74 payments — averaging $82.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$5K
- AbbVie$469
- Gilead$197
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$162
- Lilly USA, LLC$119
- Phathom Pharmaceuticals, Inc.$117
- plus $344 from 9 others
What the payments were for
- Speaking & faculty fees$4,62076%
- Food & beverage$1,46724%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 6 | $4,678 |
| AbbVie(2 entities) | 23 | $469 |
| Gilead | 10 | $197 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $162 |
| Lilly USA, LLC | 1 | $119 |
| Phathom Pharmaceuticals, Inc. | 1 | $117 |
| QOL Medical, LLC | 6 | $92 |
| Dova Pharmaceuticals | 3 | $58 |
| Ipsen Biopharmaceuticals, Inc | 2 | $46 |
| Braintree Laboratories, Inc. | 3 | $45 |
| Redhill Biopharma Inc. | 2 | $34 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $14 |
| UCB, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hepatology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 12 | $149,828 |
| XifaxanRifaximin | 31 | $111,861 |
| ZenpepLipase/Protease/Amylase | 17 | $66,816 |
| VemlidyTenofovir Alafenamide | 26 | $38,660 |
| Ursodiol | 90 | $14,477 |
| LinzessLinaclotide | 13 | $6,919 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 33 | $5,673 |
| Azathioprine | 16 | $2,091 |
| Pantoprazole Sodium | 125 | $1,216 |
| Famotidine | 44 | $914 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 13 | $845 |
| Omeprazole | 53 | $749 |
| Dicyclomine Hcl | 41 | $661 |
| Carvedilol | 72 | $629 |
| Mycophenolate Mofetil | 12 | $481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $4,678 | $149,82812 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $162 | $111,86131 claims |
| GileadVemlidy | $197 | $38,66026 claims |
| AbbVieLinzess | $469 | $6,91913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other hepatology in Miami
- Brett FortuneMiami$147K
- Cynthia LevyMiami$88K
- Leopoldo ArosemenaMiami$4K
- Eugene SchiffMiami$405
- Patricia JonesMiami$229
- Mina ShakerMiami$105
- Lennox JeffersMiami$0
- Shady GuirguisOrlando$100K
- Miguel MalespinTampa$64K
- Arvind Rangarajan MuraliOrlando$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.